# Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)

> **NCT02612077** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 765 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **OTHER:** Observational Chemotherapy
- **DRUG:** Concomitant Bevacizumab

## Key facts

- **NCT ID:** NCT02612077
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 765 (ACTUAL)
- **Last updated:** 2016-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612077, "Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02612077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*